Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Neurotoxicity Syndromes 2Adenocarcinoma of Lung 2Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Paresthesia 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Diseases 1Anemia 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Anastrozole 8exemestane 7Trastuzumab 7Letrozole 7palbociclib 6Docetaxel 6abemaciclib 5Fulvestrant 5ribociclib 4pyrotinib 4entinostat 4Cyclophosphamide 4Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Diseases × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡